UC active | UC remission | Non-IBD controls | |
---|---|---|---|
COHORT 1 (microarray analysis) | |||
Number | 15 | 8 | 13 |
Gender (M/F) | 4/11 | 3/5 | 5/8 |
Age (years) | 42.4±9.1 | 49.4±11.7 | 41.6±12.4 |
Duration of disease (years) | 6.6±5.2 | 12.4±8.8 | – |
Extension of disease* | 0/8/7 | 1/5/2 | – |
Medication† | 4/8/1/2 | 5/3/0/0 | – |
COHORT 2 (Real-time RT-PCR) | |||
Number | 8 | 12 | 10 |
Gender (M/F) | 5/3 | 6/6 | 3/7 |
Age (years) | 49.5±17.3 | 40.5±11.2 | 42.7±9.9 |
Duration of disease (years) | 3.6±3.9 | 10.3±6.3 | – |
Extension of disease* | 2/5/1 | 1/7/4 | – |
Medication† | 3/1/1/3 | 2/5/0/5 | – |
COHORT 3 (immunohistochemistry analysis) | |||
Number | 7 | 9 | 7 |
Gender (M/F) | 5/2 | 7/2 | 2/5 |
Age (years) | 48±17.9 | 58.6±14.3 | 45.6±19.5 |
Duration of disease (years) | 6.3±6.6 | 11.4±5.4 | – |
Extension of disease* | 0/4/3 | 2/3/4 | – |
Medication† | 1/5/1/0 | 4/4/0/1 | – |
*Proctitis/Left-sided colitis/Pancolitis.
†5ASA/Azathioprine/Steroids/no treatment.
IBD, inflammatory bowel disease; UC, ulcerative colitis.